Pyridine

Pyridine

SCHEMBL1164077

NC(=O)O.c1ccncc1

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 4/20 0.60
TSHR P16473 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
F7 P08709 1/20 0.48
F3 P13726 1/20 0.48
SARM1 Q6SZW1 1/20 0.48
SIRT2 Q8IXJ6 1/20 0.48
SIRT6 Q8N6T7 1/20 0.48
SIRT1 Q96EB6 1/20 0.48
SIRT3 Q9NTG7 1/20 0.48
SIRT5 Q9NXA8 1/20 0.48
SIRT4 Q9Y6E7 1/20 0.48
ACHE P22303 1/20 0.47
ALDH1A1 P00352 2/20 0.44
APP P05067 1/20 0.44
GAA P10253 1/20 0.44
HCAR3 P49019 1/20 0.44
HCAR2 Q8TDS4 1/20 0.44
MKNK1 Q9BUB5 2/20 0.40
MKNK2 Q9HBH9 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL9065525 1.00 NAPRT (0.60) NAPRTTSHRTDP1F7F3
Pyridine SCHEMBL27840495 0.97 NAPRT (0.56) NAPRTTSHRTDP1F7F3
Pyridine SCHEMBL1070164 0.93 NAPRT (0.60) NAPRTTSHRTDP1F7F3
Pyridine SCHEMBL27474886 0.90 NAPRT (0.56) NAPRTTSHRTDP1F7F3
Pyridine SCHEMBL27643283 0.90 NAPRT (0.56) NAPRTTSHRTDP1F7F3
Pyridine SCHEMBL27461077 0.90 NAPRT (0.56) NAPRTTSHRTDP1F7F3
Pyridine SCHEMBL27887446 0.90 NAPRT (0.56) NAPRTTSHRTDP1F7F3
Pyridine SCHEMBL27738793 0.90 NAPRT (0.56) NAPRTTSHRTDP1F7F3
Pyridine SCHEMBL28762998 0.90 NAPRT (0.56) NAPRTTSHRTDP1F7F3
Pyridine SCHEMBL27811338 0.90 NAPRT (0.56) NAPRTTSHRTDP1F7F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1984891-B Process for the preparation of carboxamide pyridine derivatives useful as intermediates in the synthesis of NK-1 receptor antagonists HOFFMANN LA ROCHE 2012-08-08 CN claimed
EP-1776342-B1 PROCESS FOR PREPARING CARBOXAMIDE PYRIDINE DERIVATIVES USED AS INTERMEDIATES IN THE SYNTHESIS OF NK-1 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2011-03-02 EP claimed
US-7384939-B2 Process for preparation of pyridine derivatives of NK-1 receptor antagonist ROCHE COLORADO CORPORATION (US) 2008-06-10 US claimed
CN-1984891-A Process for the preparation of carboxamide pyridine derivatives useful as intermediates in the synthesis of NK-1 receptor antagonists HOFFMANN LA ROCHE (CH) 2007-06-20 CN claimed
EP-1776342-A1 PROCESS FOR PREPARING CARBOXAMIDE PYRIDINE DERIVATIVES USED AS INTERMEDIATES IN THE SYNTHESIS OF NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-04-25 EP claimed
CN-1898201-A Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents SENTION INC (US) 2007-01-17 CN claimed
US-20060014959-A1 Process for preparation of pyridine derivatives of NK-1 receptor antagonist ROCHE COLORADO CORPORATION (US) 2006-01-19 US claimed
WO-2006002860-A1 PROCESS FOR PREPARING CARBOXAMIDE PYRIDINE DERIVATIVES USED AS INTERMEDIATES IN THE SYNTHESIS OF NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-01-12 WO claimed
EP-0231837-B1 PROCESS FOR THE PREPARATION OF WATER SOLUBLE PHTHALOCYANINE DYES HOECHST AKTIENGESELLSCHAFT (DE) 1989-08-02 EP claimed
EP-0231837-A2 Process for the preparation of water soluble phthalocyanine dyes HOECHST AKTIENGESELLSCHAFT (DE) 1987-08-12 EP claimed
JP-52039681-A None JP disclosed
JP-5213877-A None JP disclosed
EP-4384165-B1 MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2025-07-09 EP disclosed
WO-2023106278-A1 AGRICULTURAL CHEMICAL COMPOSITION AND METHOD FOR PRODUCING SAME 株式会社MMAG 2023-06-15 WO disclosed
US-11447503-B2 Pyridine carbamates and their use as GLUN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2022-09-20 US disclosed
EP-0092384-B1 IMPROVED PROCESS FOR MAKING THIOBISCARBAMATES UNION CARBIDE CORPORATION (US) 1986-12-30 EP disclosed
EP-0138002-A2 Herbicidal agents containing a photosynthesis inhibitor herbicide together with pyridincarboxylic-acid amides BAYER AG (DE) 1985-04-24 EP disclosed
US-4146642-A ANTHELMINTICS MERCK & CO., INC. (US) 1979-03-27 US disclosed
US-4105767-A ANTHELMINTICS MERCK & CO., INC. (US) 1978-08-08 US disclosed
JP-S5239681-A BASICCSUBSTITUTED PYRIDINE CARBONIC ACID AMIDE AND ACID ADDITION PRODUCT PREPARATION METHOD THEREOF AND MEDICAL MIXTURE CONTAINING THESE COMPOUNDS CIBA GEIGY AG 1977-03-28 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11447503-B2 Pyridine carbamates and their use as GLUN2B receptor modulators GRIN2B, GRIN2A, GRIN1 NAPRT 479/4885TSHR 379/4885TDP1 3581/4885
US-20060014959-A1 Process for preparation of pyridine derivatives of NK-1 receptor antagonist BDKRB1, TACR1, NPSR1 NAPRT 1531/4885TSHR 169/4885TDP1 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.